In agreement with this idea, a recent study showed that a pre-exposure to cisplatin is sufficient to raise an ATR-dependent adaptive response to subsequent cisplatin treatments that involves transcription of the PRIMPOL protein to rescue fork degradation and to promote fork restart in brca1 cancer cells (77). Here, PRIMPOL is linked to cancer.